Website intended for a NZ health professional readership
Current international guidelines for type 2 diabetes management include the use of two new classes of medication: sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists, in people with established kidney disease, heart disease or heart failure or with high cardiovascular risk. Rinki Murphy, associate professor of medicine at the University of Auckland and an endocrinologist specialising in diabetes and obesity, reviews how to utilise the benefits of these medications, including how to start them in this patient population, alongside usual management strategies for type 2 diabetes
In this article, Sue Frankland looks at the global problem of wastage of medications, including causes such as overprescribing and non-adherence. She also presents information from her master’s dissertation on how people understand, and respond to, medication expiration dates
Why recognising the signs of dehydration is important...
